These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6869191)

  • 1. Verapamil in atrial fibrillation: The expected, the unexpected, and the unknown.
    Schwartz JB
    Am Heart J; 1983 Jul; 106(1 Pt 1):173-6. PubMed ID: 6869191
    [No Abstract]   [Full Text] [Related]  

  • 2. Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction.
    Klein HO; Kaplinsky E
    Am J Cardiol; 1982 Oct; 50(4):894-902. PubMed ID: 6751065
    [No Abstract]   [Full Text] [Related]  

  • 3. Atrial fibrillation in the Wolff-Parkinson-White syndrome: effects of verapamil and procainamide.
    Laufer N; Crevey B
    Ariz Med; 1985 Mar; 42(3):150-3. PubMed ID: 3994532
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical use of verapamil.
    Vohra JK
    Drugs; 1977 Mar; 13(3):219-24. PubMed ID: 321206
    [No Abstract]   [Full Text] [Related]  

  • 5. Augmented ventricular rate following verapamil treatment for atrial fibrillation with Wolff-Parkinson-White syndrome.
    Rowland TW
    Pediatrics; 1983 Aug; 72(2):245-6. PubMed ID: 6866612
    [No Abstract]   [Full Text] [Related]  

  • 6. [Wolff-Parkinson-White syndrome and verapamil: apropos of a case of ventricular fibrillation].
    Michel B; Goy JJ; Kappenberger L
    Schweiz Med Wochenschr; 1989 May; 119(19):630-4. PubMed ID: 2740877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnesium reversal of digoxin-facilitated ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome.
    Merrill JJ; DeWeese G; Wharton JM
    Am J Med; 1994 Jul; 97(1):25-8. PubMed ID: 8030653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil.
    Gulamhusein S; Ko P; Carruthers SG; Klein GJ
    Circulation; 1982 Feb; 65(2):348-54. PubMed ID: 7053894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misuse of verapamil in pre-excited atrial fibrillation.
    Garratt C; Antoniou A; Ward D; Camm AJ
    Lancet; 1989 Feb; 1(8634):367-9. PubMed ID: 2563516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of isoptin in auricular fibrillation in a patient with Wolff-Parkinson-White syndrome].
    Golitsyn SP; Sokolov SF; Mazur NA
    Kardiologiia; 1979 Jul; 19(7):102-5. PubMed ID: 470312
    [No Abstract]   [Full Text] [Related]  

  • 11. Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation.
    Strasberg B; Sagie A; Rechavia E; Katz A; Ovsyscher IA; Sclarovsky S; Agmon J
    Cardiovasc Drugs Ther; 1989 Jan; 2(6):801-6. PubMed ID: 2488095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verapamil induced premature ventricular beats before reversion of supraventricular tachycardia.
    Vohra J; Peter T; Hunt D; Sloman G
    Br Heart J; 1974 Dec; 36(12):1186-93. PubMed ID: 4441450
    [No Abstract]   [Full Text] [Related]  

  • 13. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome.
    Gulamhusein S; Ko P; Klein GJ
    Am Heart J; 1983 Jul; 106(1 Pt 1):145-7. PubMed ID: 6869178
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
    Harper RW; Whitford E; Middlebrook K; Federman J; Anderson S; Pitt A
    Am J Cardiol; 1982 Dec; 50(6):1323-30. PubMed ID: 7148709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome with atrial fibrillation.
    Jacob AS; Nielsen DH; Gianelly RE
    Ann Emerg Med; 1985 Feb; 14(2):159-60. PubMed ID: 3970402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma digoxin concentrations in patients with atrial fibrillation and indications for the association with other antiarrhythmic agents.
    Cargnelli G; Domeneghetti F; Ferrari M; Malacini P; Roberti G
    Int J Clin Pharmacol Biopharm; 1977 Aug; 15(8):384-8. PubMed ID: 892956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation.
    Bennett DH
    Chest; 1978 Dec; 74(6):624-8. PubMed ID: 738119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Discrepant effects of oral and intravenous verapamil on A-V conduction in patients with ventricular preexcitation and atrial fibrillation].
    Petri H; Kafka W; Rudolph W
    Herz; 1983 Jun; 8(3):144-52. PubMed ID: 6347850
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias.
    Rinkenberger RL; Prystowsky EN; Heger JJ; Troup PJ; Jackman WM; Zipes DP
    Circulation; 1980 Nov; 62(5):996-1010. PubMed ID: 7418184
    [No Abstract]   [Full Text] [Related]  

  • 20. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome.
    McGovern B; Garan H; Ruskin JN
    Ann Intern Med; 1986 Jun; 104(6):791-4. PubMed ID: 3706931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.